RP 5063

Drug Profile

RP 5063

Alternative Names: RP 5000; RP5063

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reviva Pharmaceuticals
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Dopamine D4 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizoaffective disorder; Schizophrenia
  • Phase I Attention-deficit hyperactivity disorder; Bipolar disorders; Major depressive disorder; Psychotic disorders
  • Preclinical Autistic disorder; Gilles de la Tourette's syndrome; Pulmonary arterial hypertension

Most Recent Events

  • 17 Oct 2017 Reviva Pharmaceuticals plans to initiate a phase II trial for Pulmonary arterial hypertension in early 2018
  • 17 Nov 2016 RP 5063 receives Orphan Drug status for Pulmonary arterial hypertension in USA
  • 19 May 2016 Preclinical trials in Pulmonary arterial hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top